Resistance Training’s Ability to Prevent Cancer-induced Muscle Atrophy Extends Anabolic Stimulus
Authors:
- Poliana C. MarinelloPMPoliana C. Marinello
- Rafael DeminiceRDRafael Deminice
- 16 March 2021
- journal article
- research article
- Published by Wolters Kluwer Health in Medicine & Science in Sports & Exercise
- Vol. 53 (8) , 1572-1582
Abstract
Purpose: This study aimed to determine the role of mammalian target of rapamycin (mTORC1) activation and catabolic markers in resistance training’s (RT) antiatrophy effect during cachexia-induced muscle loss. Methods: Myofiber atrophy was induced by injecting Walker 256 tumor cells into rats exposed or not exposed to the RT protocol of ladder climbing. The role of RT-induced anabolic stimulation was investigated in tumor-bearing rats with the mTORC1 inhibitor rapamycin, and cross-sectional areas of skeletal muscle were evaluated to identify atrophy or hypertrophy. Components of the mTORC1 and ubiquitin–proteasome pathways were assessed by real-time polymerase chain reaction or immunoblotting. Results: Although RT prevented myofiber atrophy and impaired the strength of tumor-bearing rats, in healthy rats, it promoted activated mTORC1, as demonstrated by p70S6K’s increased phosphorylation and myofiber’s enlarged cross-sectional area. However, RT promoted no changes in the ratio of p70S6K to phospho-p70S6K protein expression while prevented myofiber atrophy in tumor-bearing rats. Beyond that, treatment with rapamycin did not preclude RT’s preventive effect on myofiber atrophy in tumor-bearing rats. Thus, RT’s ability to prevent cancer-induced myofiber atrophy seems to be independent of mTORC1’s and p70S6K’s activation. Indeed, RT’s preventive effect on cancer-induced myofiber atrophy was associated with its capacity to attenuate elevated tumor necrosis factor α and interleukin 6 as well as to prevent oxidative damage in muscles and an elevated abundance of atrogin-1. Conclusions: By inducing attenuated myofiber atrophy independent of mTORC1’s signaling activation, RT prevents muscle atrophy during cancer by reducing inflammation, oxidative damage, and atrogin-1 expression.Keywords
This publication has 48 references indexed in Scilit:
- IL-6 regulation on skeletal muscle mitochondrial remodeling during cancer cachexia in the Apc Min/+ mouseSkeletal Muscle, 2012
- Muscle oxidative capacity during IL-6-dependent cancer cachexiaAmerican Journal of Physiology-Regulatory, Integrative and Comparative Physiology, 2011
- Combined Resistance and Aerobic Exercise Program Reverses Muscle Loss in Men Undergoing Androgen Suppression Therapy for Prostate Cancer Without Bone Metastases: A Randomized Controlled TrialJournal of Clinical Oncology, 2010
- During muscle atrophy, thick, but not thin, filament components are degraded by MuRF1-dependent ubiquitylationJournal of Cell Biology, 2009
- Cachexia: A new definitionClinical Nutrition, 2008
- The E3 Ligase MuRF1 Degrades Myosin Heavy Chain Protein in Dexamethasone-Treated Skeletal MuscleCell Metabolism, 2007
- Rapamycin inhibits the growth and muscle-sparing effects of clenbuterolJournal of Applied Physiology, 2007
- Effects of Tumor Necrosis Factor-Alpha on the 26S Proteasome and 19S Regulator in Skeletal Muscle of Severely Scalded MiceJournal of Burn Care & Research, 2006
- Clinical Pharmacokinetics of EverolimusClinical Pharmacokinetics, 2004
- Advanced oxidation protein products as a novel marker of oxidative stress in uremiaKidney International, 1996